Millions of people cannot
access essential medicines they need for deadly diseases like malaria,
tuberculosis (TB) and HIV/AIDS. There is good information on the need for drugs
for these diseases but until now, no global estimate of the impact drugs are
having on this burden.
This paper presents a model measuring companies’ key
malaria, TB and HIV/AIDS drugs’ consequences for global health (global-health-impact.org). It
aggregates drugs’ impacts in several ways–by disease, country and
originator-company. The methodology can be extended across diseases as well as
drugs to provide a more extensive picture of the impact companies’ drugs are
having on the global burden of disease.
The study suggests that key malaria, TB
and HIV/AIDS drugs are, together, ameliorating about 37% of the global burden
of these diseases and Sanofi, Novartis, and Pfizer’s drugs are having the
largest effect on this burden.
Moreover, drug impacts vary widely across
countries. This index provides important information for policy makers,
pharmaceutical companies, countries, and other stake-holders that can help
increase access to essential medicines.
Below: Impact scores of
individual drugs by rank. A graph of the comparative impact of the top
10 drugs ranked from 1 (highest impact) to 10 (lowest impact). Blue bars
represent malaria drugs, yellow bars represent TB drugs, and red bars represent
HIV drugs.
Below: Total impact scores
for drugs aggregated by disease. What
proportion of aggregate drug impacts is attributable to Malaria, TB, and HIV.
Below: Estimated Disability
Adjusted Life Years averted in each country.
A graph showing how many DALYs are averted globally, divided by
country.
Below: Impact scores of
individual drugs by rank for Nigeria. A graph of the comparative impact
of 15 drugs ranked from 1 (highest impact) to 15 (lowest impact) for the
treatment of Malaria in Nigeria. Blue bars represent malaria drugs, yellow bars
represent TB drugs, and red bars represent HIV drugs
Below: Aggregated drug
impact scores for each company. The proportion of total impact
attributable to companies based upon the drugs they have originated.
Full article at: http://goo.gl/YoZ5LR
By:
More at: https://twitter.com/hiv_insight
No comments:
Post a Comment